Mycophenolate is an immunosuppressant drug with a variety of different clinical uses, including the prevention of rejection following organ transplant surgery and the treatment of rheumatic conditions, including Lupus.
More recently, it has been researched as a possible treatment for pain. Now, a pilot and feasibility study has commenced at the Walton Centre Trial Unit in Liverpool, under the lead of Dr Andreas Goebel, Senior Lecturer at the University of Liverpool, as to its effectiveness as a treatment for pain in longstanding Complex Regional Pain Syndrome (CRPS).
It is now well established that the body’s immune system is involved in CRPS. The study – Mycophenolate Treatment for Longstanding Complex Regional Pain Syndrome (MYPS I) – aims to investigate whether, in addition to other forms of treatment for CRPS, Mycophenolate can relieve the chronic pain caused by the condition.
Dr Goebel is one of the world’s leading researchers on CRPS and in another article, we have recently looked at his trial of intravenous immunoglobulin (the LIPS trial) for the condition. Some of our client’s at BLB Solicitors have been involved in the LIPS trial and we understand that early results are quietly encouraging.